A new antiviral drug that induces mutations in the genetic material of influenza virus is highly effective in treating influenza infection in animals and human airway tissue and could be a groundbreaking advance in influenza therapy, according to a study by the Institute for Biomedical Sciences at Georgia State University.
The antiviral drug blocks RNA polymerase, the enzyme that plays a central role in replicating the genome of influenza virus, causing mutations in the viral genome. If enough mutations occur, the genome becomes nonfunctional and the virus cannot replicate. The findings were published online on Oct. 23 in Science Translational Medicine.
“The compound is highly efficacious against influenza,” said Dr. Richard Plemper, senior author of the study and a professor in the Institute for Biomedical Sciences. “It’s orally available, it’s broad spectrum against all influenza virus strains tested, and most important it establishes a high barrier against viral escape from inhibition.”
Influenza, caused by a contagious respiratory virus, is characterized by fever, cough, headache, muscle and joint pain, severe malaise, sore throat and sometimes gastrointestinal symptoms. Patients in higher risk groups, such as older adults and individuals with compromised immune systems, frequently require hospitalization. Each year, seasonal influenza results in 30,000 to 80,000 fatalities in the United States. The seasonal flu vaccine is only moderately effective, and licensed antivirals are compromised by rapidly emerging viral resistance to the drugs.
In the study, the new antiviral drug was tested in ferrets, the most informative animal model for human influenza disease, against various strains that include seasonal and pandemic viruses, such as the swine-origin influenza virus responsible for a 2009 pandemic. The researchers found that the antiviral drug efficiently inhibited replication of all of these strains. Virus burden dropped rapidly after treatment, and the duration of fever was significantly shorter in treated ferrets than in control animals that did not receive the drug.
“We think that the next generation of influenza antiviral drugs must not only be efficacious and safe, but also address the resistance problem,” said Dr. Mart Toots, first author of the study and a research assistant professor associated with Dr. Plemper’s lab in the Institute for Biomedical Sciences.
That is where the new drug comes in. Through a combination of conventional and ultra-deep sequencing, Toots has demonstrated in collaboration with Dr. Alex Greninger at the University of Washington that it is very challenging for the virus to find a viable way to avoid the compound.
“We have not identified specific resistance mutations yet and are confident to say that the genetic barrier against viral resistance is high,” Plemper said. “We believe that this compound has high clinical potential as a next-generation influenza drug that combines key antiviral features.”
The Latest on: Influenza
via Google News
The Latest on: Influenza
- Farm Pride Foods culling 30% of hens after H7N7 Avian influenza outbreakon August 9, 2020 at 5:38 pm
An outbreak of Avian influenza has struck ASX-listed poultry producer Farm Pride Foods Lethbridge facility, wiping out 18-23m in revenue.
- Kanazawa University research: Real-time observation of structural dynamic of influenza A hemagglutinin during viral entryon August 7, 2020 at 4:16 am
Researchers at Kanazawa University report in Nano Letters a high-speed atomic force microscopy study on a biological event ...
- Avian Influenza Vaccines Sales Market Study for 2020 to 2026 providing information on Key Players, Growth Drivers and Industry challengeson August 6, 2020 at 5:49 pm
The Avian Influenza Vaccines Sales Market is segmented on the lines of its application, type and regional. Basis ...
- Eosinophils contribute to antiviral host defense mechanisms during influenzaon August 5, 2020 at 9:30 pm
Eosinophils residing in the airways of mice respond to influenza A virus infection through alterations in surface expression of various markers necessary for migration and cellular immunity responses, ...
- Influenza A virus directly modulates eosinophil responseson August 5, 2020 at 1:10 pm
Eosinophils residing in the airways of mice respond to influenza A virus (IAV) infection through alterations in surface expression of various markers necessary for migration and cellular immunity ...
- Dr. Roach: Anti-Parkinson’s medication also helps prevent influenzaon August 3, 2020 at 9:04 pm
Amantadine was approved by the Food and Drug Administration in 1968 as a preventive and treatment for the Asian influenza pandemics ...
- As the 1918 influenza pandemic raged in the US, masks took a role in political and cultural warson August 3, 2020 at 9:41 am
More than a century ago, masks became the facial front lines in the battle against influenza. But as they have now, the masks also stoked political division.
- Global Influenza Diagnostics Market 2020-2024 - Surge in Number of Genetic Characterization Studies on Influenza Viruson July 31, 2020 at 5:46 am
The "Global Influenza Diagnostics Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The influenza diagnostics market is poised to grow by $ 1.32 bn during 2020-2024 progres ...
- Rapid Influenza Diagnostic Tests Market with Impact of COVID-19 Highlights (2020-2024)| Rising Demand For POCT to boost the Market Growth | Technavioon July 31, 2020 at 12:00 am
Technavio has been monitoring the rapid influenza diagnostic tests market and it is poised to grow by USD 0.89 billion during 2020-2024. The report offers an up-to-date ...
- Seqirus Begins Shipping 2020/21 Influenza Vaccines to U.S. Marketon July 30, 2020 at 5:30 pm
Seqirus has started shipping its portfolio of seasonal influenza vaccines to United States (U.S.) customers for the upcoming 2020/21 U.S. influenza season ...
via Bing News